Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals has reported Notes Payables over the past 3 years, most recently at $3.0 million for Q4 2023.

  • For Q4 2023, Notes Payables changed 0.0% year-over-year to $3.0 million; the TTM value through Dec 2023 reached $3.0 million, changed 0.0%, while the annual FY2023 figure was $3.0 million, 0.0% changed from the prior year.
  • Notes Payables for Q4 2023 was $3.0 million at Indivior Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
  • Over five years, Notes Payables peaked at $3.0 million in Q4 2021 and troughed at $3.0 million in Q4 2021.
  • A 3-year average of $3.0 million and a median of $3.0 million in 2021 define the central range for Notes Payables.
  • On a YoY basis, Notes Payables climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
  • Year by year, Notes Payables stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
  • Business Quant data shows Notes Payables for INDV at $3.0 million in Q4 2023, $3.0 million in Q4 2022, and $3.0 million in Q4 2021.